Catégorie : Dossiers scientifiques

Minor Cannabinoids of Cannabis sativa L., Fabian Thomas & Oliver Kayser, 2019

Minor Cannabinoids of Cannabis sativa L. Fabian Thomas & Oliver Kayser Journal of Medical Science, 2019, 88, (3), 141-149. Doi : 10.20883/jms.367   ABSTRACT Cannabinoids from Cannabis sativa L. play an important role as natural products in clinics. The major cannabinoids compromise tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) and its decarboxylated analogs. In this review, we focus on often neglected minor cannabinoids and discuss biosynthetic and chemical degradation routes to other neglected cannabinoids in Cannabis sativa starting from THCA, CBDA and cannabichromenic acid (CBCA). Based on the literature, patents and scientific reports, essential routes for the chemical modifi cation of cannabinoids are discussed to explain [...]

Lire la suite

Determination of cannabinoids in Cannabis sativa L. samples for recreational, medical, and forensic purposes by reversed-phase liquid chromatography-ultraviolet detection, Sanja Zivovinovic, et al., 2018

Determination of cannabinoids in Cannabis sativa L. samples for recreational, medical, and forensic purposes by reversed-phase liquid chromatography-ultraviolet detection Sanja Zivovinovic, Ruth Alder, Martina D. Allenspach and Christian Steuer Journal of Analytical Science and Technology, 2018, 9, 27, 1-10 doi : 10.1186/s40543-018-0159-8   Abstract Background : Currently, an increasing demand of cannabis-derived products for recreational and medical use is observed. Therefore, the reliable and fast quantification of cannabinoids in hemp samples is essential for the control of product from Cannabis sativa, L. strains. In general, gas chromatography (GC) is the method of choice for the quantification of cannabinoids whereas this method is time consuming and the [...]

Lire la suite

Δ 9‑Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels : An Assessment on Cannabis Duplicity, Swapnali Chetia & Gaurab Borah, 2020

Δ 9‑Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels : An Assessment on Cannabis Duplicity Swapnali Chetia · Gaurab Borah Natural Products and Bioprospecting, 2020, 10, 285–296 doi : 10.1007/s13659-020-00263-z   Abstract Δ9-tetrahydrocannabinol (THC) of cannabis is the main psychoactive component which is a global significant concern to human health. Evaluation on THC reported its drastic effect on the brain dopaminergic (DAergic) system stimulating mesolimbic DA containing neurons thereby increasing the level of striatal DA. Cannabidiol (CBD), with its anxiolytic and anti-psychotic property, is potent to ameliorate the THC-induced DAergic variations. Legal authorization of cannabis use and its analogs in most countries led to [...]

Lire la suite

IACM : Le premier webinaire gratuit de l’IACM commence dans 3 heures : Dr Roger Pertwee

Dans 3 heures, le premier webinaire de la série d'événements gratuits de l'IACM commencera, qui se déroulera jusqu'au 3 décembre 2020. Tous les webinaires peuvent être consultés gratuitement jusqu'au 31 mars 2021. Il n'y a donc aucun problème si vous manquez un rendez-vous. O. k. Vous pouvez copier le Magath ici https://new.cannabis-med.org/e2020 15 octobre 2020, 18 heures (CET) Dr. Roger Pertwee Les utilisations thérapeutiques potentielles de certains cannabinoïdes dérivés du cannabis et synthétiques révélées par leurs propriétés pharmacologiques -- Quels sont les médicaments cannabinoïdes approuvés qui ont déjà été développés ? -- Existe-t-il des cannabinoïdes végétaux (phytocannabinoïdes) ayant des propriétés pharmacologiques, pour lesquels des applications thérapeutiques [...]

Lire la suite

L’ÉCHEC ANNONCÉ DE L’AMENDE FORFAITAIRE DÉLICTUELLE ÉTENDUE AU DÉLIT D’USAGE DE STUPÉFIANTS NOVEMBRE 2018, LIVRE BLANC INTER-ASSOCIATIF SUR L’ARTICLE 37 DU PROJET DE LOI DE PROGRAMMATION 2018-2022 ET DE RÉFORME DE LA JUSTICE SYNTHÈSE, NOVEMBRE 2018

L’ÉCHEC ANNONCÉ DE L’AMENDE FORFAITAIRE DÉLICTUELLE ÉTENDUE AU DÉLIT D’USAGE DE STUPÉFIANTS NOVEMBRE 2018 LIVRE BLANC INTER-ASSOCIATIF SUR L’ARTICLE 37 DU PROJET DE LOI DE PROGRAMMATION 2018-2022 ET DE RÉFORME DE LA JUSTICE SYNTHÈSE NOVEMBRE 2018   UN CADRE LÉGAL CONTRAIGNANT MAIS INEFFICACE La politique française en matière de drogues est encadrée par des dispositifs qui trouvent leur fondement dans la loi n° 070-1320 du 31 décembre 1970 relative aux mesures sanitaires de lutte contre la toxicomanie et la répression du trafic et de l’usage illicite de substances vénéneuses dont l’objectif est « un monde sans drogues ». Cette loi instaure un régime d’exception à l’encontre [...]

Lire la suite

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years, Raphael G. dos Santos et al., 2016

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi and Jaime E. C. Hallak Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3) 193–213 Doi : 10.1177/2045125316638008   Abstract : To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have [...]

Lire la suite

Recent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens, Adam L. Halberstadt, 2015

Recent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens Adam L. Halberstadt Behavioral Brain Research, 2015, 15, 277, 99–120. doi : 10.1016/j.bbr.2014.07.016   Abstract Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse [...]

Lire la suite

Pharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review, Karli K. Kondo et al., 2020,

Pharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review Karli K. Kondo, PhD; Benjamin J. Morasco, PhD; Shannon M. Nugent, PhD; Chelsea K. Ayers, MPH; Maya E. O’Neil, PhD; Michele Freeman, MPH, and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020, 172, 398-412. doi : 10.7326/M19-1105   Background : Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. Purpose : To review the benefits and risks of pharmacotherapies for the treatment of CUD. Data Sources : MEDLINE, PsycINFO, Cochrane Database of Systematic Reviews, and clinical trial registries from inception through September 2019. Study Selection : Pharmacotherapy trials [...]

Lire la suite

Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies, Sagnik Bhattacharyya et al., 2012,

Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A. Crippa and Philip K. McGuire Current Pharmaceutical Design, 2012, 18, 5045-5054   Abstract Pharmacological challenge in conjunction with neuroimaging techniques has been employed for over two decades now to understand the neural basis of the cognitive, emotional and symptomatic effects of the main ingredients of cannabis, the most widely used illicit drug in the world. This selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main cannabinoids [...]

Lire la suite

What Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ?, Robin M. Murray et al., 2013

What Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ? Robin M. Murray, Alessandra Paparelli, Paul D. Morrison, Arianna Marconi, and Marta Di Forti American Journal of Medical Genetics, Part B, 2013, 162B, 661–670. Doi : 10.1002/ajmg.b.32177   When drug-induced psychoses were first identified in the mid- 20th century, schizophrenia was considered a discrete disease with a likely genetic cause. Consequently, drug-induced psychoses were not considered central to understanding schizophrenia as they were thought to be phenocopies rather than examples of the illness secondary to a particular known cause. However, now that we know that schizophrenia is a clinical syndrome with [...]

Lire la suite